Goldman Sachs Group Inc Taysha Gene Therapies, Inc. Put Options Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding TSHA
# of Institutions
154Shares Held
244MCall Options Held
107KPut Options Held
17K-
Rtw Investments, LP New York, NY25MShares$76.8 Million0.89% of portfolio
-
Ra Capital Management, L.P. Boston, MA23.6MShares$72.3 Million1.19% of portfolio
-
Avoro Capital Advisors LLC New York, NY21.7MShares$66.6 Million0.91% of portfolio
-
Morgan Stanley New York, NY16.9MShares$51.8 Million0.0% of portfolio
-
Octagon Capital Advisors LP New York, NY12.6MShares$38.7 Million11.04% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $148M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...